Apparatus and method for determining a parameter indicative of the progress of an extracorporeal blood treatment
10786613 ยท 2020-09-29
Assignee
Inventors
Cpc classification
A61M2205/52
HUMAN NECESSITIES
International classification
Abstract
An apparatus and process for extracorporeal treatment of blood (1) comprising a treatment unit (2), a blood withdrawal line (6), a blood return line (7), a preparation line (19) and a spent dialysate line (13). A control unit (10) is configured to calculate values of a parameter relating to treatment effectiveness based on measures of lactate or citrate or acetate concentration in the spent dialysate line (13).
Claims
1. An apparatus for extracorporeal treatment of blood comprising: a preparation line having one end configured for being connected to an inlet of a secondary chamber of a treatment unit, a semi-permeable membrane separating said secondary chamber from a primary chamber of the same treatment unit; a spent dialysate line having one end configured for being connected to an outlet of said secondary chamber; and a control unit configured for commanding execution of the following steps: causing a fresh treatment liquid to flow in the preparation line towards the secondary chamber at a flow rate, the treatment liquid including lactate; causing a used treatment liquid to flow in the spent dialysate line at a flow rate; receiving one or more measured values of a parameter related to the concentration of lactate in the used treatment liquid flowing in the spent dialysate line; and computing at least one value of a parameter indicative of the effectiveness of the extracorporeal blood treatment based on: said one or more measured values of the parameter related to the concentration of lactate of the used treatment liquid; and at least one of: said flow rate of fresh treatment liquid and said flow rate of used treatment liquid.
2. The apparatus according to claim 1, wherein the control unit is further configured for receiving one or more values of a parameter related to the concentration of lactate of the fresh treatment liquid flowing in the preparation line.
3. The apparatus according to claim 2, wherein the step of receiving one or more values of a parameter related to the concentration of lactate of the fresh treatment liquid flowing in the preparation line includes one of: measuring one or more actual values of the parameter related to the concentration of lactate of the fresh treatment liquid flowing in the preparation line, retrieving from a memory one or more preset values of the parameter related to the concentration of lactate of the fresh treatment liquid flowing in the preparation line, or receiving from a user interface one or more input values of the parameter related to the concentration of lactate of the fresh treatment liquid flowing in the preparation line.
4. The apparatus according to claim 2, wherein computing at least one value of a parameter indicative of the effectiveness of the extracorporeal blood treatment is based on: said one or more measured values of the parameter related to the concentration of lactate of the used treatment liquid; said one or more values of the parameter related to the concentration of lactate of the fresh treatment liquid; and at least one of: said flow rate of fresh treatment liquid or said flow rate of used treatment liquid.
5. The apparatus according to claim 4, wherein the step of causing a fresh treatment liquid to flow in the preparation line comprises the sub-step of maintaining, at least for a time interval, the concentration of the lactate in the fresh treatment liquid constant at a set value which represents the value of the parameter related to the concentration of lactate of the fresh treatment liquid used for computing the at least one value of a parameter indicative of the effectiveness of the extracorporeal blood treatment.
6. The apparatus according to claim 5, wherein said one or more measured values of the parameter related to the concentration of lactate in the used treatment liquid are representative of measures of the parameter related to the concentration of lactate taken during one of: said time interval, or a further time interval delayed by a hydraulic delay with respect to said time interval.
7. The apparatus according to claim 1, wherein the control unit is further configured for: receiving a total treatment time, which is a time during which the apparatus operates with blood in the extracorporeal circuit and a patient connected to the extracorporeal circuit; maintaining the concentration of the lactate in the fresh treatment liquid constant at said set value during a time interval lasting for a significant portion of the treatment time; and calculating a plurality of consecutive times during said time interval the value of the parameter indicative of the effectiveness of the extracorporeal blood treatment, wherein said significant portion of the treatment time comprising a portion of time is selected from the group consisting of: at least 10% of said total treatment time (Tt), at least 30% of said total treatment time (Tt), at least 70% of said total treatment time (Tt), and the entire treatment total time (Tt).
8. The apparatus according to claim 1, further comprising: an outlet lactate concentration sensor connected to the control unit, the outlet lactate concentration sensor being operative at one of: said spent dialysate line, a line connected to the spent dialysate line, or a line connected to the outlet of said secondary chamber, wherein the outlet lactate concentration sensor is configured for measuring one or more real values of the lactate concentration lactate in the fluid exiting from the secondary chamber, and wherein the control unit is configured to receive, a measured value or values of the parameter related to the concentration of lactate in the used treatment liquid, the one or more measured real values of the lactate concentration detected by the outlet lactate concentration sensor.
9. The apparatus according to claim 1, wherein the apparatus includes at least a blood pump configured to operate on an extracorporeal blood circuit connectable to the primary chamber of said blood treatment unit, said control unit being connected to the blood pump and being configured to: operate the blood pump to cause flow of a patient's blood in the extracorporeal blood circuit at a blood flow rate, receive or store a value representative of the concentration of lactate in the patient's blood or in a blood component of the patient's blood, and wherein the parameter indicative of the effectiveness of the extracorporeal blood treatment is calculated based on: at least one measured value of the parameter related to the concentration of lactate in the used treatment liquid; at least one measured value of the parameter related to the concentration of lactate in the fresh treatment liquid; said flow rate of fresh treatment liquid; and said value representative of the concentration of lactate in the patient's blood or in the blood component of the patient's blood.
10. The apparatus according to claim 6, wherein, at least during said time interval or during said further time interval, the control unit is configured to keep constant the flow rate of fresh treatment liquid in the preparation line, the flow rate of the patient's blood in the extracorporeal blood circuit, and the flow rate of ultrafiltration flow through the semipermeable membrane.
11. The apparatus according to claim 1, wherein the parameter indicative of the effectiveness of the extracorporeal blood treatment is lactate dialysance, which is calculated using the following formula:
D=(Qdin(CdinCdout)+QPCdout)/(CdinCbin) where D is the calculated value of dialysance for lactate, Cd.sub.out is the measured value of the parameter related to the concentration of lactate of the used treatment liquid, Cd.sub.in is measured value of the parameter related to the concentration of lactate of the fresh treatment liquid, Qd.sub.in is the flow rate of fresh treatment liquid; Cb.sub.in is the value representative of the concentration of lactate in blood or in a blood component, and Q.sub.F is the value of ultrafiltration flow rate through the semipermeable membrane.
12. The apparatus according to claim 1, wherein the control unit is configured for causing the fresh treatment liquid to flow in the preparation line towards the secondary chamber at a constant lactate concentration, which is set at a set value comprised between 35 mmol/l and 45 mmol/l.
13. The apparatus according to claim 9, wherein the value representative of the concentration of lactate in blood or in a blood component is a known value selected in the range comprised between 1 and 5 mmol/l.
14. The apparatus according to claim 1, wherein the parameter indicative of the effectiveness of the extracorporeal blood treatment is lactate dialysance, and wherein the control unit is configured to calculate the dialysance for a given solute different from lactate using: the calculated value of the lactate dialysance, and one or more established relationships between the value of a mass transfer coefficient for lactate to the value of a mass transfer coefficient for the given solute, the mass transfer coefficient reflecting a solute diffusion through the membrane.
15. The apparatus according to claim 14, wherein the parameter indicative of the effectiveness of the extracorporeal blood treatment is lactate dialysance, and wherein the control unit is configured to calculate dialysance for a given solute different from lactate, the calculation of dialysance for the given solute comprising: deriving a mass transfer coefficient for lactate of the membrane of the treatment unit from the calculated value of the dialysance for lactate; determining a mass transfer coefficient of the membrane of the treatment unit for the given solute based on the value of the mass transfer coefficient for lactate; calculating the dialysance for the given solute based on the mass transfer coefficient for the given solute; and wherein the lactate dialysance and the dialysance for the given solute different from lactate are calculated at same values of: the flow rate of fresh treatment liquid, the ultrafiltration flow rate through the semipermeable membrane, and the blood flow rate in the extracorporeal circuit.
16. The apparatus according to claim 14, wherein the control unit is further configured for: identifying the solute for which dialysance is to be calculated; determining if a mass transfer time of the solute through red blood cells is greater, optionally at least 5 times greater, than a blood dwell time of blood flowing through the blood treatment unit; and using the value of the plasma flow rate at the inlet of the blood treatment unit as an effective value of the blood flow rate for the purpose of calculating the solute mass transfer coefficient, if it has been determined that the mass transfer time of the solute through red blood cells is greater, optionally 5 times greater, than a blood dwell time in the blood treatment unit, where Qp.sub.in=(1Hct)*Qb.sub.in, and with Qp.sub.in being the plasma flow rate at the inlet of the blood treatment unit, Hct being the hematocrit of the patient's blood in the arterial line at the inlet of the blood treatment unit, and Qb.sub.in, being the blood flow rate at the inlet of the blood treatment unit.
17. The apparatus according to claim 14, wherein the mass transfer coefficient for lactate of the membrane of the treatment unit is derived by: measuring or calculating the value of dialysance for lactate, in particular at zero ultrafiltration; deriving a mass transfer coefficient for lactate of the membrane of the treatment unit from: the calculated value of the dialysance for lactate, in particular at zero ultrafiltration, one or more of values of: the flow rate of fresh treatment liquid, the flow rate of spent dialysate liquid, the ultrafiltration flow rate through the semipermeable membrane, and the blood flow rate or the plasma flow rate, in particular one of the plasma flow rate at the inlet of the blood treatment unit and the blood flow rate at the inlet of the blood treatment unit; wherein the mass transfer coefficient for the given solute is derived using one or more established relationships between the value of the mass transfer coefficient for lactate to the value of the mass transfer coefficient for the given solute; and wherein the dialysance of the given solute is calculated based on: one or more values of: the flow rate of fresh treatment liquid, the flow rate of spent dialysate liquid, the ultrafiltration flow rate through the semipermeable membrane, one of the blood flow rate or the plasma flow rate, in particular one of the plasma flow rate at the inlet of the blood treatment unit and the blood flow rate at the inlet of the blood treatment unit, and the determined mass transfer coefficient for the given solute.
18. The apparatus according to claim 17, wherein the step of deriving a mass transfer coefficient for lactate of the membrane of the treatment unit comprises: measuring or calculating the value of dialysance for lactate at zero ultrafiltration, and calculating the mass transfer coefficient for lactate of the membrane of the treatment unit using the calculated value of the dialysance for lactate at zero ultrafiltration, wherein the step of calculating dialysance of the given solute comprises: first determining the value of the dialysance for the given solute, at zero ultrafiltration, based upon: the determined mass transfer coefficient for the given solute; and one of: the flow rate of fresh treatment liquid and the flow rate of spent dialysate liquid; or one or the blood flow rate or the plasma flow rate, in particular one of the plasma flow rate at the inlet of the blood treatment unit and the blood flow rate at the inlet of the blood treatment unit; and second determining dialysance for the given solute at non-zero ultrafiltration based upon: the determined value of the dialysance for the given solute at zero ultrafiltration, and the value of the ultrafiltration flow rate; or the determined value of the dialysance for the given solute at zero ultrafiltration, the value of the ultrafiltration flow rate through the semipermeable membrane, and one of the blood flow rate or plasma flow rate, in particular one of the plasma flow rate at the inlet of the blood treatment unit and the blood flow rate at the inlet of the blood treatment unit.
19. The apparatus according to claim 1, wherein the parameter indicative of the effectiveness of the extracorporeal blood treatment comprises a lactate dialysis dose delivered over a reference time period and wherein the control unit is configured to calculate the lactate dialysis dose by: determining the total effluent volume flow through the spent dialysate line in the course of the reference time period, and measuring the lactate concentration of said total effluent volume, or wherein the control unit is configured to calculate lactate dialysis dose by: receiving said one or more values of a parameter related to the concentration of lactate of the fresh treatment liquid flowing in the preparation line measured during the reference time period, receiving values of the following flow rates, which remain constant during the time period: blood flow rate, one of fresh treatment liquid flow rate or used treatment liquid flow rate, and, if present, ultrafiltration flow rate, calculating a value of lactate dialysance for said time period, and calculating a lactate dialysis dose for said time period multiplying the duration of the time period times the lactate dialysance-determined for the same time period.
20. The apparatus according to claim 1, wherein the control unit is configured to automatically trigger a new computation of at least one value of said parameter indicative of the effectiveness of the extracorporeal blood treatment every time the control unit receives an indication that there has been a change or detects a change in one or more of: blood flow rate, fresh treatment liquid flow rate, used treatment liquid flow rate, and, if present, ultrafiltration flow rate.
Description
DESCRIPTION OF THE DRAWINGS
(1) Aspects of the invention are shown in the attached drawings, which are provided by way of non-limiting example, wherein:
(2)
(3)
(4)
(5)
(6)
(7)
DETAILED DESCRIPTION
(8) Non-limiting embodiments of an apparatus 1 for extracorporeal treatment of bloodwhich may implement innovative aspects of the inventionare shown in
(9)
(10) The apparatus 1 comprises a treatment unit 2 (such as a hemofilter, a hemodiafilter, a dialyzer and the like) having a primary chamber 3 and a secondary chamber 4 separated by a semi-permeable membrane 5; depending upon the treatment, the membrane of the filtration unit may be selected to have different properties and performances.
(11) A blood withdrawal line 6 is connected to an inlet of the primary chamber 3, and a blood return line 7 is connected to an outlet of the primary chamber 3. In use, the blood withdrawal line 6 and the blood return line 7 are connected to a needle or to a catheter or other access device (not shown) which is then placed in fluid communication with the patient vascular system, such that blood may be withdrawn through the blood withdrawal line, flown through the primary chamber and then returned to the patient's vascular system through the blood return line. An air separator, such as a bubble trap 8 may be present on the blood return line; moreover, a safety clamp 9 controlled by a control unit 10 may be present on the blood return line downstream the bubble trap 8. The control unit may comprise a digital processor (CPU) and a memory (or memories), an analogical type circuit, or a combination thereof as explained in greater detail in below section dedicated to the control unit. A bubble sensor 8a, for instance associated to the bubble trap 8 or coupled to a portion of the line 7 between bubble trap 8 and clamp 9 may be present: if present, the bubble sensor is connected to the control unit 10 and sends to the control unit signals for the control unit to cause closure of the clamp 9 in case one or more bubbles above certain safety thresholds are detected. As shown in
(12) An operator may enter a set value for the blood flow rate Qb: the control unit 10, during treatment, is configured to control the blood pump based on the set blood flow rate. It is noted that the control unit 10 may also be connected to a user interface 12, for instance a graphic user interface, which receives operator's inputs (such as the set value for the blood flow rate) and displays the apparatus outputs. For instance, the graphic user interface 12 may include a touch screen for both displaying outputs and allowing user entries, or a display screen and hard keys for entering user's inputs, or a combination thereof.
(13) A spent dialysate line 13 configured for evacuating an effluent fluid coming from the secondary chamber 4 is connected, at one end, to an outlet of the secondary chamber 4 and, at its other end, to a waste which may be a discharge conduit or an effluent fluid container 14 (dashed lines in
(14) The apparatus of
(15) In the example of
(16) In accordance with one aspect of the present invention the buffer is or comprises lactate. In particular, the first container may host a lactate concentrate solution: the metering pump(s) and the dialysis pump may be controlled such as to generate a fresh treatment fluid at a desired lactate concentration (e.g. at 40 mmol/l of lactate concentration). Within the meaning of the present description and claims, lactate includes L-lactate, D-lactate, any mixture of D-lactate with L-lactate, or other lactate based compositions. Note that alternatively to the on line preparation section 100, the apparatus 1 may use one or more preformed bags of fresh treatment fluid at the desired concentration for the buffer (lactate) and for the substances (electrolytes, nutrients etcetera).
(17) The embodiment of
(18) In each one of the above described embodiments, flow sensors 110, 111 (either of the volumetric or of the mass type) may be used to measure flow rate in each of the lines. Flow sensors are connected to the control unit 10. In the example of
(19) In the example of
(20) From a structural point of view one or more, containers 104, 107, 16, 23 may be disposable plastic containers. The blood lines 6, 7 lines and the filtration unit may also be plastic disposable components which may be mounted at the beginning of the treatment session and then disposed of at the end of the treatment session. Pumps, e.g. peristaltic pumps or positive displacement pumps, have been described for regulating fluid flow through each of the lines; however, it should be noted that other flow regulating devices may alternatively be adopted such as for example valves or combinations of valves and pumps. The scales may comprise piezoelectric sensors, or strain gauges, or spring sensors, or any other type of transducer able to sense forces applied thereon. As already explained, the conductivity sensors may be replaced by concentration sensors.
(21) Measure of the Parameter Indicative of Effectiveness of Blood Treatment
(22) The operation of the above apparatus for measuring a parameter indicative of the effectiveness of the blood treatment is now described, with reference to the attached figures and to the flowchart of
(23) The control unit 10 is configured to operate the blood pump and cause flow of a patient's blood in the extracorporeal blood circuit at a blood flow rate Qb: for example the blood flow rate may be set by the user acting on the user interface 12, or it may be pre-stored in a memory associated to the control unit or it may be automatically calculated set by the control unit based on certain operative conditions (e.g. keeping pressure upstream the blood pump above a minimum threshold); the control unit 10 also commands pumps 105, 108 and 21 and is configured for causing the preparation of a treatment liquid in section 100 and the flow of the freshly prepared treatment liquid in line 19 and into the secondary chamber 4. The control unit may receive, e.g. via user interface 12, at least one prescription value Cd.sub.set for lactate concentration Cd.sub.in of the treatment liquid which should be kept during the treatment (step 201) and control the first metering pump accordingly. Note that the control unit 10 may also receive set values for the conductivity of the fresh treatment liquid, or for the concentration of at least one substance (e.g. sodium and/or other electrolytes) in the fresh treatment liquid and, based on this value(s), control the second and any further metering pump(s) accordingly.
(24) Note that the prescription value for lactate concentration or for other substances may be constant or it may vary according to a prefixed profile during the treatment.
(25) For example, referring to
Q.sub.F=Q.sub.INF1+Q.sub.INF2+Q.sub.WLREquation (1)
Qd.sub.in=Qd.sub.outQ.sub.F Equation 1A
(26) the control unit may receive set values for n2 of said flow rates (Q.sub.INF1, Q.sub.INF2, Q.sub.F, Qd.sub.in, Qd.sub.out, Q.sub.WLR), and calculate the remaining 2 using equations 1 and 1A.
(27) The above also applies to the configuration of
Q.sub.F=Q.sub.WLR Equation 1
Qd.sub.in=Qd.sub.outQ.sub.F Equation 1A
(28) and therefore it is sufficient for the control unit to know for example the value of the desired weight loss rate and that of one of Qd.sub.in, Qd.sub.out to have all settings necessary to control the apparatus fluid lines.
(29) In accordance with aspects of the invention, the control unit 10 is further configured for receiving one or more values of a parameter related to the concentration of lactate Cd.sub.in of the fresh treatment liquid flowing in the preparation line 19: for instance control unit 10, e.g. acting on preparation section 100, may keep the concentration of the lactate Cd.sub.in in the fresh treatment liquid constant at a set value Cd.sub.set (e.g., imposed by the operator via user interface 12). Cd.sub.set would therefore represent the value of the parameter related to the concentration of lactate Cd.sub.in of the fresh treatment liquid. In most treatments, the concentration of lactate in the fresh treatment liquid is kept at a same set value Cd.sub.set all along the treatment time Tt; it is however not excluded that the concentration of lactate in the fresh dialysis liquid may be changed and e.g., kept at a first constant value Cd.sub.set1 for a time interval T.sub.1 and then moved up or down to a different constant value Cd.sub.set2 for a subsequent time interval T.sub.2 (see
(30) The control unit 10 is also configured for receiving one or more measured values of a parameter related to the concentration of lactate Cd.sub.out in the used treatment liquid flowing in the spent dialysate line 13 and for computing at least one value of a parameter D, KT indicative of the effectiveness of the extracorporeal blood treatment. At this purpose, the apparatus 1 may include an outlet lactate concentration sensor 50, which may be operative at said spent dialysate line 13 and be connected to the control unit: this latter is configured to receive, as measured value or values, of the parameter related to the concentration of lactate Cd.sub.out in the used treatment liquid, one or more measured values of the lactate concentration Cd.sub.out detected in real time by the lactate concentration sensor. Use of a lactate concentration sensor 50 located in the spent dialysate line 13 allows to measure the instantaneous value of lactate concentration and thus the control unit 10 may be configured to receive said measured value(s) of instantaneous lactate concentration(s) and to calculate in real time instantaneous value(s) of the parameter D, KT indicative of the effectiveness of the extracorporeal blood treatment. This may be repeated a plurality of times in the course of the treatment thereby monitoring in real time the value of the effectiveness parameter, still with no negative impact on treatment prescription as lactate concentration may follow its prescribed value. The lactate concentration sensor 50 may be located in the spent dialysate line itself: for instance the lactate concentration sensor 50 may be located in a tract of the spent dialysate line upstream the branch off point 51 of the ultrafiltration line 25 (see
(31) In case of evaluation of a whole treatment session, then it may alternatively be envisaged to collect the spent fluid which has flown in the spent dialysate line (or samples of said spent fluid sampled at regular intervals) and measure the concentration of lactate in the collected fluid with an appropriate sensor. For example, in the circuit shown in
(32) In further detail and with reference to the flow chart of
(33) As mentioned, (step 203) the control unit 10 may then calculate the effectiveness parameter D, KT: the calculation may be done a plurality of consecutive times during said time interval T in order to get a reliable indication of the development of the actual effectiveness of the treatment. In particular, the control unit then calculates the value of the parameter D, KT indicative of the effectiveness of the extracorporeal blood treatment based on:
(34) the one or more measured values of the parameter related to the concentration of lactate Cd.sub.out of the used treatment liquid;
(35) the one or more values of the parameter related to the concentration of lactate Cd.sub.in of the fresh treatment liquid (in practice based on Cd.sub.set);
(36) the value of said flow rate Qd.sub.in of fresh treatment liquid or of said flow rate Qd.sub.out of used treatment liquid.
(37) Additionally, the control unit may receive or store a value representative of the concentration of lactate in blood Cb.sub.in: this value may be a constant value or a value set by the physician based on knowledge of the specific patient. The applicant noted that lactate concentration in arterial blood at the beginning of a treatment session is slightly less than 1 mmol/l and changes only slightly during the dialysis session: the average increase being between 2 and 4 mmol/liter and taking place in the first minutes of blood treatment. This means that if the calculation is made using measured values taken after the initial minutes of extracorporeal blood treatment, then considering as set value for the lactate concentration in blood e.g. 4 mmol/l does not significantly affect accuracy of the calculation of the effectiveness parameter. Thus, the control unit may accurately calculate the value of the parameter D, KT indicative of the effectiveness of the extracorporeal blood treatment based on the above indicated values and also on the value of the concentration of lactate in blood Cb.sub.in, which is normally taken between 3 and 5 mmol/l.
(38) In accordance with an aspect the parameter indicative of the effectiveness of the extracorporeal blood treatment is lactate dialysance D, and in particular effective lactate dialysance, which is calculated using the following formula:
D=(Qdin (Cdin Cdout)+QFCdout)/(Cdin Cbin)Equation (2)
(39) where
(40) D is the calculated value of dialysance for lactate,
(41) Cd.sub.out is the measured value of the parameter related to the concentration of lactate, in particular the lactate concentration, of the used treatment liquid;
(42) Cd.sub.in is measured value of the parameter related to the concentration of lactate, in particular the lactate concentration, of the fresh treatment liquid;
(43) Qd.sub.in is the flow rate of fresh treatment liquid;
(44) Cb.sub.in is the value representative of the concentration of lactate in blood or in a blood component (plasma);
(45) Q.sub.F is the value of ultrafiltration flow rate through the semipermeable membrane.
(46) When no ultrafiltration through the semipermeable membrane is present (Q.sub.F=0), then the above formula takes the following simplified form:
D=D0=(Qdin (Cdin Cdout))/(Cdin Cbin)Equation (3)
(47) Note that for the purpose of calculation of the effectiveness parameter and in particular of dialysance the control unit is configured to keep constant both the flow rate Qd.sub.in of fresh treatment liquid in the preparation line 19 and the flow rate Qb of patient's blood in the extracorporeal blood circuit; in practice while the measure(s) of Cd.sub.out is/are taken (e.g., during T or T), the concentration Cd.sub.in of lactate in the fresh treatment liquid and the flow rates of fresh treatment liquid Qd.sub.in and of blood Qb are all kept constant.
(48) The above calculated value of D is an effective dialysance and thus accounts for both the performances of the membrane of the blood treatment unit and for any recirculation at access level (i.e. recirculation of treated blood between the venous or return line and the arterial or withdrawal line of the extracorporeal blood circuit).
(49) The control unit may also be configured to determine presence or at least a suspect of the presence of recirculation at fistula level and/or to calculate an amount of recirculation at fistula level (step 204) by comparing the detected dialysance value D with a reference value (which may be a constant reference value or a value of dialysance measured for the same patient in previous treatments).
(50) Once the dialysance for lactate has been calculated, the control unit may also calculate and display (e.g., via user interface 12) the dialysance for a given solute different from lactate (step 205).
(51) In greater detail, according to a further aspect of the invention and with reference to
(52) Kdialyzer clearance/dialysance of urea/other solute,
(53) Tdialysis time,
(54) Vvolume of distribution of urea/solute, approximately equal to patient's total body water.
(55) The calculation of dialysance or clearance for the given solute (e.g. urea) comprises, for example, the following steps, which rely on use of one parameter, namely the mass transfer coefficient, which is an expression of the performance characteristics of a dialyzer membrane.
(56) In particular, in the case of purely diffusive mass transfer, dialysance or clearance may be expressed as a function of the solute mass transfer coefficient K0.A of the specific dialyzer. Mass transfer K0.A reflects solute diffusion in the dialysis membrane and fluid compartments, dependents on solute size and decreases when solute molecular weight increases. The term K0.A matches with the asymptotic dialysance the dialyzer would deliver at infinite flow rates.
(57) With the aim of calculating dialysance or clearance for the given solute (e.g. urea) different from lactate, the control unit derives first a mass transfer coefficient (K0.A).sub.lactate for lactate of the membrane of the treatment unit.
(58) For instance using the following formula, which is valid only in the case where no ultrafiltration occurs. This means Q.sub.F=0 but also that internal phenomenon of filtration/backfiltration is not considered by this equation. In these conditions inlet and outlet flow rates are equal, namely Qd.sub.in=Qd.sub.out.
(59)
(60) Note that in the above formula the value of dialysance at zero ultrafiltration is used. In case the value of dialysance (in this case lactate dialysance) at zero ultrafiltration (Q.sub.F=0) is not available then there are at least two ways to estimate dialysance D0 at zero ultrafiltration as a function of a dialysance value D obtained at non-zero filtration.
(61)
(62) Thus, in case a dialysance value D is available at non-zero ultrafiltration, above equations allows for estimating the dialysance at zero ultrafiltration D0 (step 301 in
(63) K0.A value (in particular (K0.A).sub.lactate) may then be derived from this D0 estimate using Equation 4 (step 302).
(64) Then, based on (K0.A).sub.lactate the (K0.A) value for a different solute may be calculated (step 303). As already mentioned mass transfer coefficient reflects solute diffusion in the dialysis membrane and fluid compartments, it is strongly dependent on solute size and decreases when solute molecular weight increases. Experimental data indicate that K0 (or K0.A) interpolation as a function of solute molecular weight is a power law:
(65)
(66) Where ref is a reference solute for which K0.A value is available.
(67) Above interpolation law may be valid in a reasonably wide molecular weight range, e.g. 50 to 5000 g/mole. Urea will be often taken as reference solute, being commonly monitored and representative of the smallest solutes (mw 60 g/mole). Power law coefficient b may be computed as soon as K0.A is available for two solutes of different molecular weight. In general coefficient b depends upon the properties of the membrane 5 of the treatment unit 2: the manufacture of the treatment unit generally provides data sheets with in vitro or in vivo clearance/dialysance values over a relevant range of molecular weight solutes (>1000 g/mole), which may be used to compute b.
(68) For instance the following table provides reference values of K0.A for an exemplary plausible membrane used in dialysis, and which may then be used for calculating coefficient b and then for extrapolating lactate to urea data from equation 7.
(69) TABLE-US-00001 Solute Urea Vitamin B12 Lactate mw (g/mole) 60 1335 89 K0.A (ml/min) 720 200 Power law b = 0.41 coefficient
(70) Once the (K0.A) for a solute different from lactate has been calculated, then dialysance for said different solute may be estimated for instance using the following equation (step 304 in
(71)
(72) where
(73) Qb.sub.in=value of the blood flow rate at the inlet of the treatment unit (this value is typically known as it is either set by the user or estimated with known methods e.g. by measuring the angular speed of the blood pump and the pressure regimen in the blood line),
(74) Qd.sub.in=value of the flow rate of fresh treatment liquid in the preparation line 19,
(75) QF=value of the ultrafiltration flow rate.
(76) Alternatively, once the (K0.A) for a different solute has been calculated, then dialysance may be calculated for using equation 4 (to determine dialysance at zero ultrafiltration for said given solute) and then one of equations 5 or 6 to determine dialysance at non-zero ultrafiltration for the given solute. Equation 8 may alternatively be used for computing (K0.A).sub.lactate.
(77) In summary, the control unit 10, by applying the above equations, is configured to calculate the dialysance for a given solute different from lactate from:
(78) the calculated value of the dialysance for lactate,
(79) one or more of values of: the flow rate Qd.sub.in of fresh treatment liquid, the flow rate Qd.sub.out of spent dialysate liquid, the ultrafiltration flow rate Q.sub.F through the semipermeable membrane;
(80) the blood flow rate Qb or the plasma flow rate Qp (in particular the measured or estimated values of these flow rates at the inlet of the treatment unit);
(81) one or more established relationships (e.g., known ratios) between the value of the mass transfer coefficient (K0.A).sub.lactate for lactate to the value of the mass transfer coefficient (K0.A).sub.solute for the given solute.
(82) It should be noted that the equations reported in previous section implicitly assume that blood and treatment fluid is one-phase for the given solute. This one phase model, using Qbin, provides results which although quite accurate represent a first approximation compared to reality. A more accurate model may consider that:
(83) solutes may not be evenly distributed between plasma and red blood cells (RBCs),
(84) solutes transfer across RBC membrane may be slow.
(85) According to one further aspect of the invention, depending upon the solute, instead of blood flow Qb.sub.in, equations 6 and 8 above may use plasma flow rate Qp.sub.in at the inlet of the blood treatment unit (Qp.sub.in=Qb.sub.in*(1-Hct)). Analogously, Qp.sub.in may be used in equation 4 for determining the K0.A value.
(86) In particular, equations 4 and 6 may be used with Qp.sub.in instead of Qp.sub.in, in order to arrive at the (K0.A).sub.lactate for lactate. Then, equation 7 may be used for the calculation of the K0.A value for another solute. If for instance this other solute is urea it may be reasonably assumed that no concentration gradient is present between plasma and RBCs for urea, and thus transfer through the RBC membrane is sufficiently fast with respect to the blood dwell time in the dialyzer. In such case equation 8 for the calculation of urea dialysance D may be used selecting whole blood flow rate Qb.sub.in. Instead, if dialysance of creatinine needs to be calculated, one should consider that creatinine mass transfer through RBC membrane is slow with respect to the blood dwell time in the dialyzer; consequently creatinine inside RBCs is more or less unchanged at dialyzer outlet. Thus, once K0.A is available for creatinine (e.g. via equation 7), dialysance for creatinine may be calculated with equation 8 using Qp.sub.in instead of Qb.sub.in.
(87) In summary, again referring to
(88) measuring or calculating the value of dialysance for lactate at zero ultrafiltration (step 301),
(89) deriving a mass transfer coefficient (K0.A).sub.Lactate for lactate of the membrane of the treatment unit (step 302) from:
(90) the calculated value of the dialysance for lactate at zero ultrafiltration,
(91) one or more of values of: the flow rate Qd.sub.in of fresh treatment liquid, the flow rate Qd.sub.out of spent dialysate liquid, the ultrafiltration flow rate Q.sub.F through the semipermeable membrane, the blood flow rate Qb or the plasma flow rate Qp (in particular the measured or estimated values of these flow rates at the inlet of the treatment unit); Then the control unit derives the mass transfer coefficient (K0.A).sub.solute for a given solute different from lactate (step 303) relying on one or more established ratios between the value of the mass transfer coefficient (K0.A).sub.lactate for lactate to the value of the mass transfer coefficient (K0.A).sub.solute for the given solute. Subsequently, the control unit calculates the dialysance for the given solute different from lactate (step 304) based on either equation 4 and one of equations 5 or 6 (which imply to first calculate dialysance at zero ultrafiltration), or using equation 8 (which allow direct calculation of the dialysance at non zero ultrafiltration) using Qbin or Qpin depending upon the transfer behavior of the selected solute.
(92) In other words, once the mass transfer coefficient for the given solute has been determined, dialysance may be calculated based on:
(93) the derived mass transfer coefficient for the given solute (K0.A).sub.solute; and
(94) one or more of values of: the flow rate Qd.sub.in of fresh treatment liquid, the flow rate Qd.sub.out of spent dialysate liquid, the ultrafiltration flow rate Q.sub.F through the semipermeable membrane,
(95) the blood flow rate Qb or the plasma flow rate Qp (in particular the measured or estimated values of these flow rates at the inlet of the treatment unit).
(96) In accordance with another aspect, the parameter indicative of the effectiveness of the extracorporeal blood treatment based is the lactate dialysis dose (KT).sub.lactate delivered over a reference time period T and the control unit may be configured to calculate (step 203 in
(97) The lactate dialysis dose (KT).sub.lactate delivered over a reference time period T (or the total lactate dialysis dose for lactate (KTt).sub.lactate delivered over the whole treatment time) may be determined in various ways.
(98) A first procedure may be applied if the flow rates (namely blood flow rate Qb, fresh treatment liquid flow rate Qd.sub.in, used treatment liquid flow rate Qd.sub.out and, if present, ultrafiltration flow rate Q.sub.F) remain constant during the whole treatment time Tt or at least during a reference time period T which may be a fraction of the whole treatment time. According to this first procedure, the control unit (10) may be configured to calculate lactate dialysis dose (KT).sub.lactate or (KTt).sub.lactate by:
(99) determining the total effluent volume flown in the spent dialysate line EV in the course of the reference time period T or Tt,
(100) measuring the lactate concentration of said total effluent volume,
(101) calculating KT or KTt for lactate based on the lactate concentration in blood, lactate concentration in the fresh treatment liquid and lactate concentration in said effluent volume using the following formula
(KT).sub.lactate=EV*((Cd.sub.inCd.sub.out)/(Cd.sub.inCb.sub.in))Equation (9)
or
(KTt).sub.Lactate=EV*((Cd.sub.inCd.sub.out)/(Cd.sub.inCb.sub.in))Equation (10)
(102) where
(103) EV: effluent volume during T or Tt respectively,
(104) Cd.sub.out is the lactate concentration of the used treatment liquid;
(105) Cd.sub.in is the lactate concentration of the fresh treatment liquid;
(106) Cb.sub.in is the concentration of lactate in blood or in a blood component (plasma).
(107) In case during a total treatment time Tt the flow rates (namely blood flow rate Qb, fresh treatment liquid flow rate Qd.sub.in, used treatment liquid flow rate Qd.sub.out and, if present, ultrafiltration flow rate Q.sub.F) remain constant at respective values during corresponding consecutive reference time periods Ti (each Ti being fraction of the whole treatment time), then the total dialysis dose for lactate KTt.sub.lactate may be calculated using the above process, namely equation 9, for each reference time period Ti and then making the sum of each partial dialysis dose (KT)i.sub.lactate calculated for each reference time period Ti:
(108) In other words, for each time period Ti equation 9 becomes:
(KT)i.sub.lactate=EVi*((Cd.sub.inCd.sub.out)/(Cd.sub.inCb.sub.in))
(109) where
(110) EVi: effluent volume collected during each respective time interval
(111) (Ti),
(112) Cd.sub.out is the lactate concentration of the used treatment liquid during each respective time interval (Ti),
(113) Cd.sub.in is the lactate concentration of the fresh treatment liquid during each respective time interval (Ti),
(114) Cb.sub.in is the concentration of lactate in blood or in a blood component (plasma) during each respective time interval (Ti).
(115) The total dialysis dose for lactate (KTt).sub.lactate is then determined making the sum of each partial dialysis dose for lactate (KT)i.sub.lactate for each reference time period Ti as follows:
(KTt).sub.Lactate=(KT)i.sub.lactateEquation (11)
(116) The above procedure requires that the spent dialysate line is connected to a collection container where the entire spent dialysate volume is collected or to a collection container connected with a sampling line configured for regularly, e.g., periodically, sampling representative samples of the spent dialysate over the whole treatment time or over the reference time period. Moreover, the concentration of lactate in the liquid present in the collection container (such as container 23 or container 14) at the end of the treatment may need to be measured.
(117) In the case where no representative sample(s) of the spent dialysate over the whole treatment (or over a reference time period of interest) is available, and/or flow rate changes have occurred one or more times along the treatment (or reference time period of interest), then the present invention provides for a second alternative procedure to calculate the total lactate dialysis dose (KTt).sub.Lactate over treatment time Tt. In these conditions overall lactate (KTt).sub.lactate may be estimated by making a sum of a plurality of lactate dialysis dose contributes (in a way similar to equation 11):
(KTt).sub.lactate=(KT)i.sub.lactate=(Di.sub.lactate.Math.Ti)Equation (12)
(118) In greater detail, according to a second procedure, the control unit (10) may be configured to calculate lactate dialysis dose (KT).sub.lactate by:
(119) determining lactate dialysance for a first time period (T1) during which the blood flow rate (Qb), the flow rate (Qd.sub.in) of fresh treatment liquid, and optionally ultrafiltration flow rate (Q.sub.F), are kept constant at first respective values;
(120) calculating a lactate dose for the first time period multiplying the duration of the first time period times the lactate dialysance determined for the same first time period;
(121) determining lactate dialysance for any further time period (Ti) during which the blood flow rate (Qb), the flow rate (Qd.sub.in) of fresh treatment liquid, and optionally ultrafiltration flow rate (Q.sub.F), are kept constant at further respective values;
(122) calculating a lactate dialysis dose for each one of said further time periods multiplying the duration of each further time period times the respective lactate dialysance determined for the same further time period;
(123) summing the calculated lactate doses for the first time period and for each further time period to obtain the total lactate dose for the reference period (which may be total treatment time Tt) covering the first time period and any further time period using equation 12.
(124) Finally, the invention provides for a third procedure in case where:
(125) no representative sample(s) of the spent dialysate over the whole treatment (or over a reference time period of interest) is available,
(126) flow rate changes have occurred one or more times along the treatment (or reference time period of interest),
(127) spent dialysate lactate concentration is only measured once during the treatment (or during the reference time period of interest).
(128) Under these circumstances and according to further aspects of the invention, the control unit may be configured to calculate dialysance for lactate at any given flow rate condition and consequently determine the overall lactate dose (KT).sub.lactate or (Kit).sub.lactate from the single lactate measurement, via the computation of lactate K0.A. If, for instance, we assume to have spent dialysate lactate concentration measured during a first time period (together with the values of all needed flow rates which remain constant during the first time period namely blood flow rate (Qb).sub.1, fresh treatment liquid flow rate (Qd.sub.in).sub.1 or used treatment liquid flow rate (Qd.sub.out).sub.1 and, if present, ultrafiltration flow rate (Q.sub.F).sub.1, then lactate dialysance (D1).sub.lactate for said first time period may be determined using above equation 2. Consequently, the control unit may be configured to determine the value of the lactate dialysance for a second time period (D2).sub.lactate (and in general for any further time period) at which different, but known, flow rate conditions exist based on:
(129) the value of dialysance (D1).sub.Lactate for the first time period;
(130) the values of blood flow rate (Qb).sub.2, fresh treatment liquid flow rate (Qd.sub.in).sub.2 or used treatment liquid flow rate (Qd.sub.out).sub.2 and, if present, ultrafiltration flow rate (Q.sub.F).sub.2 at the second (or further) time period.
(131) In practice, the control unit may be configured to calculate the value of dialysance (D1).sub.lactate for the first time period (relying on equation 2 and using blood flow rate (Qb).sub.1, fresh treatment liquid flow rate (Qd.sub.in).sub.1 or used treatment liquid flow rate (Qd.sub.out).sub.1 and, if present, ultrafiltration flow rate Q.sub.F1); then the control unit may calculate the mass transfer coefficient for lactate (K0.A).sub.lactate using equation 4 and one of equations 5 or 6. Thenbased on the (K0.A).sub.lactate and the values of blood flow rate (Qb).sub.2, fresh treatment liquid flow rate (Qd.sub.in).sub.2 or used treatment liquid flow rate (Qd.sub.out).sub.2 and, if present, ultrafiltration flow rate (Q.sub.F).sub.2 at the second (or further) time periodthe control unit is configured to calculate dialysance for a second time period (D2).sub.lactate using equation 4 and one of equations 5 or 6 (step represented by block 206 in
(132) Once the dialysance values for the second and any further time periods have been calculated, each dialysance value is multiplied times the respective time period thereby calculating a lactate dialysis dose for each one of said time periods; then by making the sum of the calculated lactate doses for the first time period and for each further time period (see block 203 in
(KTt).sub.actate=(K T)i.sub.lactate=(Di.sub.lactate.Math.Ti)
(133) The control unit may thus be configured to calculate the dialysis dose for the entire treatment time with knowledge of the dialysance value obtained with a single measure of spent dialysate lactate concentration, as long as there is knowledge of the flow rates (blood flow rate Qb.sub.1 . . . n, fresh treatment liquid flow rate Qd.sub.in1 . . . n or used treatment liquid flow rate Qd.sub.cut1 . . . n and, if present, ultrafiltration flow rate Q.sub.F1 . . . n) of the time periods during which said flow rates apply.
(134) Finally, in accordance with a further aspect the control unit may configured to periodically calculate the value of the parameter indicative of effectiveness (e.g., either dialysance D and/or dialysis dose KT for instance using the procedures and equations presented above) or the control unit may calculate said parameter value upon receiving an order form the user (e.g., via user interface) or the control unit may automatically trigger a new computation of the value of said parameter (D, KT) indicative of the effectiveness of the extracorporeal blood treatment every time the control unit receives an indication that there has been a change (for instance a new setting entered by a user via user interface) or detects a change (for instance a detection of a change in a real value) in one or more of following flow rates: blood flow rate (Qb), fresh treatment liquid flow rate (Qd.sub.in), used treatment liquid flow rate (Qd.sub.out) and, if present, ultrafiltration flow rate (Q.sub.F).
EXAMPLES
(135) 1. Calculation of Lactate Dialysance at Constant Blood Flow Rate, Fresh Treatment Liquid Flow Rate and Ultrafiltration Flow Rate
(136) Blood flow:
Qb=Qb.sub.in=320 ml/min
(137) Fresh treatment liquid flow rate:
Qd=Qd.sub.in=500 ml/min
(138) Ultrafiltration flow rate:
Q.sub.F=15 ml/min
(139) Lactate concentration lactate in fresh treatment liquid:
Cd.sub.in=40.0 mmol/L
(140) Patient hematocrit:
Hct=33%
(141) Lactate concentration in spent treatment liquid:
Cd.sub.out=25.8 mmol/L
(142) Plasma flow rate:
Qp=320(10.33)=214.4 ml/min
(143) Patient plasma lactate estimate:
Cb.sub.in=4 mmol/L
(144) Lactate dialysance estimate using Equation 2:
D=(5004051525.8)/(404)=186.5 ml/min
(145) 2. Calculation of Urea Dialysance at Constant Blood Flow Rate, Fresh Treatment Liquid Flow Rate and Ultrafiltration Flow Rate
(146) The same assumptions of example 1 apply.
(147) After calculation of lactate dialysance with equation 2, then dialysance at zero ultrafiltration may be estimated with equation 5 or 6.
(148) Subsequently, using equation 4, the mass transfer coefficient (K0.A).sub.lactate for lactate is determined, which is (K0.A).sub.Lactate=547 ml/min.
(149) Afterwards, using equation 7 (which requires the knowledge of the value of the mass transfer coefficient (K0.A) for two solutes), the value of the mass transfer coefficient (K0.A).sub.solute for the given solute (in this case urea) may be calculated, which is (K0.A).sub.solute=647 ml/min.
(150) Finally, using equation 8, it is possible to determine urea dialysance D.sub.ur.sub.ea=239.5 ml/min
(151) 3. Calculation of Dialysance and of Dialysis Dose Based on Knowledge of Dialysance at First Values of Blood Flow Rate, Fresh Treatment Liquid Flow Rate and Ultrafiltration Flow Rate
(152) This example shows:
(153) calculation of dialysance at first flow rate conditions defined by known values blood flow rate Qb.sub.1, fresh treatment liquid flow rate Qd.sub.in1 or used treatment liquid flow rate Qd.sub.out1 and ultrafiltration flow rate Q.sub.F1 which are stable for a first time period; the calculation is made relying on equation 1 and using a measured value of Cd.sub.out1 taken during the first time period;
(154) calculation of dialysance at second flow rate conditions of blood flow rate Qb.sub.2, fresh treatment liquid flow rate Qd.sub.in2 or used treatment liquid flow rate Qd.sub.out2 and ultrafiltration flow rate Q.sub.F2, which are stable for a second time period consecutive to the first time period;
(155) calculation of KT for the first and second time periods;
(156) calculation of total treatment time KT.
(157) First Time Period Conditions
(158) Blood flow:
Qb=Qb.sub.in=320 ml/min
(159) Fresh treatment liquid flow rate:
Qd=Qd.sub.in=500 ml/min
(160) Ultrafiltration flow rate:
Q.sub.F=15 ml/min
(161) Concentration of lactate in fresh treatment liquid:
Cd.sub.in=40.0 mmol/L
(162) Patient hematocrit:
Hct=33%
(163) Lactate concentration in spent treatment liquid:
Cd.sub.out=25.8 mmol/L
(164) Plasma flow rate:
Qp=320(10.33)=214.4 ml/min
(165) Patient plasma lactate estimate:
Cb.sub.in=4 mmol/L
(166) Second Time Period Conditions (Change of Blood Flow Rate)
(167) Blood flow:
Qb=Qb.sub.in=260 ml/min
(168) Fresh treatment liquid flow rate:
Qd=Qd.sub.in=500 ml/min
(169) Ultrafiltration flow rate:
Q.sub.F=15 ml/min
(170) Concentration of lactate in fresh treatment liquid:
Cd.sub.in=40.0 mmol/L
(171) Patient hematocrit:
Hct=33%
(172) Lactate concentration in spent treatment liquid:
Cd.sub.out=not known
Plasma flow rate:
Qp=260(10.33)=174.2 ml/min
(173) Patient plasma lactate estimate:
Cb.sub.in=4 mmol/L
(174) TABLE-US-00002 Overall Period Time Period 1 Time Period 2 treatment Time 2 h 30 1 h 30 4 h 00 Qd, Q.sub.F, Hct, Same as 3.2 Cd.sub.in Qb 320 ml/min 260 ml/min Qp 214 ml/min 174 ml/min D.sub.lactate 184.4 ml/min 161.1 ml/min K0.A.sub.lactate 565 ml/min 547 ml/min 547 ml/min K.T.sub.lactate 59.7 L 41.9 L 101.6 L
(175) Control unit
(176) As already indicated the apparatus according to the invention makes use of at least one control unit. This control unit may comprise a digital processor (CPU) with memory (or memories), an analogical type circuit, or a combination of one or more digital processing units with one or more analogical processing circuits. In the present description and in the claims it is indicated that the control unit is configured or programmed to execute certain steps: this may be achieved in practice by any means which allow configuring or programming the control unit. For instance, in case of a control unit comprising one or more CPUs, one or more programs are stored in an appropriate memory: the program or programs containing instructions which, when executed by the control unit, cause the control unit to execute the steps described and/or claimed in connection with the control unit. Alternatively, if the control unit is of an analogical type, then the circuitry of the control unit is designed to include circuitry configured, in use, to process electric signals such as to execute the control unit steps herein disclosed.
(177) While the invention has been described in connection with what is presently considered to be the most practical and preferred embodiments, it is to be understood that the invention is not to be limited to the disclosed embodiments, but on the contrary, is intended to cover various modifications and equivalent arrangements included within the spirit and the scope of the appended claims.